Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$10.15 USD
-0.20 (-1.93%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $10.15 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IOVA 10.15 -0.20(-1.93%)
Will IOVA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IOVA
Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?
AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Tops Revenue Estimates
Other News for IOVA
Interesting IOVA Put And Call Options For November 15th
Iovance Biotherapeutics call volume above normal and directionally bullish
Iovance Biotherapeutics call volume above normal and directionally bullish
November 1st Options Now Available For Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics call volume above normal and directionally bullish